UBS Group Cuts Veracyte (NASDAQ:VCYT) Price Target to $42.00
Veracyte (NASDAQ:VCYT – Free Report) had its target price cut by UBS Group from $49.00 to $42.00 in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. A number of other equities research analysts have also commented on the stock. Needham & Company […]
Veracyte (NASDAQ:VCYT – Free Report) had its target price cut by UBS Group from $49.00 to $42.00 in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. A number of other equities research analysts have also commented on the stock. Needham & Company […]
